Immunomodulating Effects of Bleomycin and its Derivatives, Peplomycin and Liblomycin on Murine Antitumour Effector Cells

Xiao-Mei Chen; Qing Wang; Rui-Kun He; Yu-Tao Li; Xiao-Yun Chen; Hiroshi Kurihara; Rong-Rong He; He, Yi-Fang Li

Immunomodulating Effects of Bleomycin and its Derivatives, Peplomycin and Liblomycin on Murine Antitumour Effector Cells

Xiao-Mei Chen, Qing Wang, Rui-Kun He, Yu-Tao Li, Xiao-Yun Chen, Hiroshi Kurihara, Rong-Rong He, He, Yi-Fang Li

Abstract

We investigated the immunomodulating effects of bleomycin and its derivatives, peplomycin and liblomycin on natural killer (NK) cells and lymphokine-activated killer (LAK) precursor cells from the spleens of C57BL/6 mice. Results showed that bleomycin and peplomycin can increase in vitro NK and LAK precursor cell activities both per spleen and per unit number (1 × 106 ) of the spleen cells as compared with normal mice from day 1 to 9, while the number of spleen cells did not increase. Meanwhile, a single administration of liblomycin caused a decrease in the number of spleen cells and the activity of LAK precursor cells per mouse spleen from day 1 and they recovered to normal levels by day 9. NK activity, which was also suppressed by liblomycin, recovered slowly but failed to reach the complete restoration by day 9. Liblomycin showed no effect on LAK precursor cell activity per unit number of spleen cells. Further study showed that these immunomodulating effects of bleomycin and its derivatives are apparently at least partially mediated by the endogenous cytokine release.

Keywords

bleomycin, peplomycin, liblomycin, natural killer cell, lymphokine-activated killer precursor cell, cytokine

Full Text:

References

Cragg GM, Kingston DGI, Newman DJ. Anticancer agents from natural products, 2nd ed., Boca Raton: CRC Press LLC;2005.

Abdul Hamied TA, Parker D, Turk JL. Potentiation of release of interleukin-2 by bleomycin. Immunopharmacology. 1986; 12(2):127–134.

Hillel AT, Samad I, Ma G, Ding D, Sadtler K, Powell JD, et al. Dysregulated macrophages are present in bleomycin-induced murine laryngotracheal stenosis. Otolaryngol Head Neck Surg. 2015;153(2):244–250.

Xu ZY, Hosokawa M, Morikawa K, Hatakeyama M, Kobayashi H. Overcoming suppression of antitumor immune reactivity in tumor-bearing rats by treatment with bleomycin. Cancer Res. 1988;8(23):6658–6663.

Williamson JD, Sadofsky LR, Hart SP. The pathogenesis of bleomycin-induced lung injury in animals and its applicability to human idiopathic pulmonary fibrosis. Exp Lung Res. 2015;41(2):57–73.

Takita T, Ogino T. Peplomycin and liblomycin, a new analogues of bleomycin. Biomed Pharmacother. 1987;41(5):219–226.

Takahashi K, Ekimoto H, Minamide S, Nishikawa K, Kuramochi H, Motegi A, et al. Liblomycin, a new analogue of bleomycin. Cancer Treat Rev. 1987;14(3–4):169–177.

Micallef M, Hosokawa M, Shibata T, Nakane A, Yang ZB, Minagawa T, et al. Immunoregulatory cytokine release in rat spleen cell cultures after treatment with bleomycin and its analogues in vivo. Cancer Immunol Immunother. 1991; 33(1):33–38.

Ryzhkov VK, Zeidlits VN, Tikhonov KB. Use of protamine sulfate as a vasodilator in liver and spleen angiography. Vestn Rentgenol Radiol. 1977;(6):41–45.

Dresp J, Schmid E, Bauchinger M. The cytogenetic effect of bleomycin on human peripheral lymphocytes in vitro and in vivo. Mutat Res. 1978;56(3):341–353.

Meyer RM, Gospodarowicz MK, Connors JM, Pearcey RG, Wells WA, Winter JN, et al. ABVD alone versus radiation-based therapy in limited-stage Hodgkin’s lymphoma. N Engl J Med. 2012;366:399–408.

Williams SD, Birch R, Einhorn LH, Irwin L, Greco FA, Loehrer PJ. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med.1987;316:1435–1440.

Bugaut H, Bruchard M, Berger H, Derangère V, Odoul L, Euvrard R, et al. Bleomycin exerts ambivalent antitumor immune effect by triggering both immunogenic cell death and proliferation of regulatory T cells. PLoS One. 2013;8(6):e65181.

Yoshida T, Ogawa M, Ota K, Yoshida Y, Wakui A, Oguro M, et al. Phase II study of NK313 in malignant lymphomas: an NK313 malignant lymphoma study group trial. Cancer Chemother Pharmacol. 1993;31(6):445–448.

Lazo JS, Braun ID, Labaree DC, Schisselbauer JC, Meandzija B, Newman RA, et al. Characteristics of bleomycin-resistant phenotypes of human cell sublines and circumvention of bleomycin resistance by liblomycin. Cancer Res. 1989;49(1): 185–190.

Chen HY, Zheng CY, Zou GL, Xie DX, Gong JP. Peplomycin induces G1-phase specific apoptosis in liver carcinoma cell line Bel-7402 involving G2-phase arrest. Acta Pharmacol Sin. 2004;25:1698–1704.

Fujimura T, Kambayashi Y, Furudate S, Kakizaki A, Haga T, Hashimoto A, et al. Immunomodulatory effects of peplomycin on immunosuppressive and cytotoxic cells in the lesional skin of cutaneous squamous cell carcinoma. Dermatology. 2015;230(3):250–255.

Schwartz HS, Grindey GB. Adriamycin and daunorubicin: a comparison of antitumor activities and tissue uptake in mice following immunosuppression. Cancer Res. 1973;33(8):1837–1844.

Refbacks

There are currently no refbacks.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Journal of Pharmaceutical and Biomedical Sciences